FDA Approves Expanded Indication for Camzyos for Symptomatic Obstructive Hypertrophic Cardiomyopathy
FDA has expanded Camzyos's approval to treat symptomatic obstructive hypertrophic cardiomyopathy in pediatric patients as young as 12.
News|Podcasts|February 10, 2025
Revolutionizing Patient Adherence: Leveraging AI for Personalized Engagement
Author(s)Miranda Schmalfuhs
Bill Grambley, CEO of AllazoHealth, delves into the potential of AI to revolutionize patient engagement and adherence.
Advertisement
In this episode of the Pharmaceutical Executive podcast, Bill Grambley, CEO of AllazoHealth, explores:
- How AI can potentially revolutionize patient engagement and adherence
- Utilizing patient-level data and predictive modeling
- How AI can identify individual needs and preferences
- The importance of ethical considerations and data privacy when leveraging AI in healthcare
- and more!
Advertisement
Related to this article
Real-world data from Novo's Octane study show patients who switched from injectable GLP-1 therapy to oral semaglutide lost an average of 4.1% of their body weight within three months.
FDA this week cleared three new treatments: Lilly's Olumiant for adolescent alopecia areata, AbbVie's Juvmo for Parkinson's disease, and Mirum and Incyte's Atebrioz for the rare bone disorder FOP.
Compounding pharmacies that set their own safety and accreditation standards now stand the best chance of keeping patient access intact before heavier regulation does it for them.
FDA approves Merck and Eisai's Welireg-Lenvima combination for advanced kidney cancer, a platform-deal roundup covers Novo Nordisk, Genentech, and Roche's tie-ups with Nanexa, Earendil Labs, and Atavistik Bio, and Ron Lanton examines the fight to regulate pharmacy benefit managers.
FDA has approved Welireg plus Lenvima for previously treated advanced clear cell renal cell carcinoma.
InnoCare Pharma and Eli Lilly ink a multibillion-dollar research collaboration, FDA approves Lilly's once-weekly insulin Onswik for type 2 diabetes, and Jen Lamppa talks fixing clinical trial patient enrollment with real-world data.
FDA approves Onswik, Eli Lilly's once-weekly basal insulin for adults with type 2 diabetes.
Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: Foghorn Therapeutics & Eli Lilly Discontinue Development of FHD-909
2
Roundup: Novartis & Abogen Enter Licensing and Option Agreement, AstraZeneca and Daiichi Sankyo Enter Clinical Collaboration with Summit Therapeutics
3
New U.S. Guidance Lays Out Exemptions for 100% Tariffs: Report
4
Foghorn Therapeutics & Eli Lilly Halt Fhd-909 Development Following Phase I Data
5